Drugs / BnH-015B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06535308 | Oct 2024 → Apr 2026 overdue | Alzheimer disease | BnH Research | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BnH-015B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06535308 ↗ |
| Action | Activate | “targets the GluN2B binding site on NMDA receptors and positively modulates” NCT06535308 ↗ |
| Modality | Small molecule | “BnH-015B is a small molecule compound” NCT06535308 ↗ |
| Route | Oral | “After oral administration” NCT06535308 ↗ |